Trial Profile

Phase III trial of NLX P101 in patients with Parkinson's disease.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NLX P101 (Primary)
Indications Parkinson's disease
Focus Registrational; Therapeutic Use
Sponsors Neurologix

Most Recent Events

11 Aug 2022 According to a MeiraGTx media release, company expects to initiate enrollment in this study during the second half of 2022 with material manufactured in its cGMP facility in London, United Kingdom.
16 Mar 2011 Trial is still being planned.
07 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com